Cantor Fitzgerald Predicts Gilead Sciences FY2025 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Gilead Sciences in a research note issued to investors on Friday, April 25th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will post earnings per share of $7.96 for the year, up from their prior estimate of $7.93. Cantor Fitzgerald has a "Overweight" rating and a $125.00 price objective on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share.

Several other research firms have also commented on GILD. Piper Sandler boosted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Morgan Stanley lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $109.43.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $103.17 on Monday. The company has a market capitalization of $128.46 billion, a PE ratio of 278.84, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a 50-day simple moving average of $109.21 and a two-hundred day simple moving average of $98.33. Gilead Sciences has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.08. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. During the same period last year, the company posted ($1.32) earnings per share.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently bought and sold shares of the company. FMR LLC grew its position in shares of Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP raised its stake in Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after buying an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after buying an additional 749,047 shares during the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $1,789,254,000. Finally, Northern Trust Corp increased its holdings in shares of Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after acquiring an additional 2,458,954 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of the company's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the transaction, the chief financial officer now owns 171,223 shares of the company's stock, valued at $17,502,415.06. This represents a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 302,785 shares of company stock valued at $30,540,875. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.06%. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.